ICP-192 is novel compound against target gene abnormalities in solid tumorwith  patent application filed in China and world-wide . Mutations in target gene are identified in multiple solid tumors, making it a potential therapeutic target challenging indications such as Gastric, Cholangiocarcinoma and urothelial cancer.. ICP-192 is in a Phase I trial in China now.

•    Gastric cancer is the second leading malignant tumor in both incidence and mortality rate in China. Most patients are diagnosed at advanced stage and require systemic treatment. ICP-192 offers potential therapeutic option for patients with gastric cancer, cholangiocarcinoma, bladder cancer and liver cancer in China.